CKD

Nephrology·MeSH: Heart Diseases

Prevalence

10760.8 / 100K

Incidence

273.3 / 100K/yr

28 drugs in development·18 companies·2 clinical trials

Drug Pipeline by Phase

Approved(12)

Drug	Company
auryxia	KERYX BIOPHARMACEUTICALS INC (KERYX)
cinacalcet	DR REDDYS LABORATORIES LTD (RDY)
doxercalciferol	Amneal Pharmaceuticals, Inc. (AMRX)
EVRENZO (爱瑞卓®) / roxadustat	KYNTRA BIO INC. (KYNB)
inpefa	LEXICON PHARMACEUTICALS, INC. (LXRX)
Jardiance	ELI LILLY & Co (LLY)
Jardiance®	ELI LILLY & Co (LLY)
rayaldee	OPKO HEALTH, INC. (OPK)
sevelamer carbonate	Impax Laboratories, LLC (IPXL)
sevelamer carbonate	DR REDDYS LABORATORIES LTD (RDY)
Vafseo	Akebia Therapeutics, Inc. (AKBA)
XPHOZAH	ARDELYX, INC. (ARDX)

Phase 3(5)

Drug	Company
Auryxia	Akebia Therapeutics, Inc. (AKBA)
bardoxolone	REATA PHARMACEUTICALS INC (RETA)
ctap101	OPKO HEALTH, INC. (OPK)
react	PROKIDNEY CORP. (PROK)
veverimer	Tricida, Inc. (TCDA)

Phase 2(2)

Drug	Company
mze782	Maze Therapeutics, Inc. (MAZE)
RDX013	ARDELYX, INC. (ARDX)

Phase 1(2)

Drug	Company
rilparencel	PROKIDNEY CORP. (PROK)
vonsetamig	REGENERON PHARMACEUTICALS, INC. (REGN)

Preclinical(5)

Drug	Company
alln-346	Allena Pharmaceuticals, Inc. (ALNA)
matloc	MARIZYME, INC. (MRZM)
matloc 1	MARIZYME, INC. (MRZM)
matloc 2	MARIZYME, INC. (MRZM)
RDX020	ARDELYX, INC. (ARDX)

Unknown(1)

Drug	Company
noninterventional	REGENERON PHARMACEUTICALS, INC. (REGN)

BLA Filed(1)

Drug	Company
oxylanthanum carbonate	Unicycive Therapeutics, Inc. (UNCY)

BioSniper tracks 28 drugs in development for CKD across 18 companies.

There are 2 clinical trials targeting CKD tracked by BioSniper.

The estimated prevalence of CKD is approximately 10760.8 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.